- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-radial axial spondyloarthritis
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 668KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 141KB)
Bimekizumab – March 2024
Bimekizumab (nr axSpA): Injection 160 mg in 1 mL single use pre filled syringe, Injection 160 mg in 1 mL single use pre filled pen; Bimzelx®
Last updated
30 May 2025